|
|
 |
|
Viewing report
|
|
|
|
OTC Triptans in New Zealand
Euromonitor International, March 2012, Pages: 30
In June 2006, sumatriptan was reclassified from a prescription medicine to a restricted medicine (sold by a pharmacist in a pharmacy). This reclassification applied to packs of no more than two 50mg tablets. As a result of this reclassification, three different triptan products were commonly available, Sumagran Active, Imigran and Arrow Sumatriptan. In May 2010, Pharmac announced that it would stop subsidising Imigran and Sumagran Active and begin subsidising Arrow-Sumatriptan by Arrow...
The OTC Triptans in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the OTC Triptans market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
|
|
|
|
